- Lobbying
- Daron AND Watts
Lobbying Arrangements Results for 'Daron Watts'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act |
Shire Pharmaceuticals LLC
Biopharmaceuticals research and manufacturing; health products |
THE WATTS GROUP PLLC | |||
Details Medical innovation, gene therapy, health care costs Gene therapy innovation State Medicaid system, innovation, Value Based Arrangements |
Novartis
|
THE WATTS GROUP PLLC | |||
Details Disaster relief |
Copart, Inc.
|
SIDLEY AUSTIN LLP | |||
Details HR 2055 - Provisions relating to health and human services funding, Center for Disease Control and Prevention, burden of disease study on repiratory syncytial virus |
MedImmune LLC
|
SIDLEY AUSTIN LLP | |||
Details Issues relating to regulation of natural products, including food, nutritional supplements and natural cosmetics |
Natural Products Association
|
SIDLEY AUSTIN LLP | |||
Details Regulation of electronic nicotine delivery products as a less harmful alternative for adult smokers. Regulation of electronic nicotine delivery system products as a less harmful alternative for adu... |
Juul Labs Inc.
|
THE WATTS GROUP PLLC | |||
Details Medicare annual payment update |
Assistive Technology Group
|
SIDLEY AUSTIN LLP | |||
Details Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392 |
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION
|
SIDLEY AUSTIN LLP | |||
Details Issues relating to 510K clearance for medical devices regulated under the Federal Food, Drug and Cosmetic Act |
St. Jude Medical, Inc.
Medical device manufacturer |
SIDLEY AUSTIN LLP | |||
Details Support of the Ban Asbestos in America Act |
National Stone, Sand and Gravel Association
|
SIDLEY AUSTIN LLP | |||
Details Issues involving rules related to school lunch and breakfast programs, and other food service and nutrition issues |
Aramark
|
SIDLEY AUSTIN LLP | |||
Details Changes to Medicare and Medicaid Services (CMS) 340B program related improvements and issues |
Eli Lilly and Company
Pharmaceutical product development |
SIDLEY AUSTIN LLP | |||
Details Medicare |
Shire Pharmaceuticals LLC
|
SIDLEY AUSTIN LLP | |||
Details Department of Commerce/Trade remedies issues process including S.1702 and H.R.2945 (Fairness in Respondent Selection Act of 2015) |
Catalyst Paper
|
SIDLEY AUSTIN LLP | |||
Details Advocacy efforts relating to the drug-discount program under Section 340B of the Public Health Services Act, and healthcare deficit reduction proposals |
Grifols Inc.
|
SIDLEY AUSTIN LLP | |||
Details Educate federal agencies and congressional offices on the health policy reasons for the Medicare program to maintain its December 2011 guidance on servicing hospital equipment, including medical im... |
Bayer Healthcare
Pharmaceutical manufacturer |
SIDLEY AUSTIN LLP | |||
Details Patient access to abuse deterrent pain relief drugs |
Purdue Pharma L.P.
|
SIDLEY AUSTIN LLP | |||
Details Access to prescription drugs and payment/reimbursement related issues, including patient access under Medicare Part D. |
Sunovion Pharmaceuticals Inc.
|
SIDLEY AUSTIN LLP |